{"transactions":[{"id":4618320,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":14989,"kind":"person","name":"Vousden Karen H","position":1,"cik":"0001723884","reported_name":"Vousden Karen H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-15T20:58:41.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or September 11, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":37.44,"expiration_date":"2036-09-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001723884-26-000005","document":"form4-09152026_080937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000172388426000005/form4-09152026_080937.xml","form_type":"4"}},{"id":704314,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29077,"kind":"person","name":"Craver Josiah","position":1,"cik":"0002038400","reported_name":"Craver Josiah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO"}}],"security":"Performance-Based Stock Option (right to buy)","published_at":"2026-07-23T20:15:06.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":30824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the \"Stock Price Hurdle\") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the \"Performance Period\"), the option will be forfeited in its entirety."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety."}],"balance_after":30824,"derivative":{"exercise_price":28.37,"expiration_date":"2036-07-20","underlying":"Common Stock","underlying_shares":30824},"source":{"system":"sec-edgar","filing":"0002038400-26-000004","document":"form4-07232026_040703.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000203840026000004/form4-07232026_040703.xml","form_type":"4"}},{"id":704313,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance-Based Stock Option (right to buy)","published_at":"2026-07-23T20:15:05.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":398018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the \"Stock Price Hurdle\") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the \"Performance Period\"), the option will be forfeited in its entirety."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety."}],"balance_after":398018,"derivative":{"exercise_price":28.37,"expiration_date":"2036-07-20","underlying":"Common Stock","underlying_shares":398018},"source":{"system":"sec-edgar","filing":"0002111813-26-000012","document":"form4-07232026_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000012/form4-07232026_040701.xml","form_type":"4"}},{"id":722179,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T00:09:53.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":600,"price":24.22,"value":14532.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of\nthe Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":46688,"source":{"system":"sec-edgar","filing":"0001780030-26-000006","document":"form4-07022026_120749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000006/form4-07022026_120749.xml","form_type":"4"}},{"id":722178,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T00:09:53.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":4400,"price":23.4,"value":102960.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of\nthe Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":46088,"source":{"system":"sec-edgar","filing":"0001780030-26-000006","document":"form4-07022026_120749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000006/form4-07022026_120749.xml","form_type":"4"}},{"id":722177,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T00:09:53.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":4255,"price":24.98,"value":106289.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":41688,"source":{"system":"sec-edgar","filing":"0001780030-26-000006","document":"form4-07022026_120749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000006/form4-07022026_120749.xml","form_type":"4"}},{"id":722176,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T00:09:53.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":1638,"price":23.88,"value":39115.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":37433,"source":{"system":"sec-edgar","filing":"0001780030-26-000006","document":"form4-07022026_120749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000006/form4-07022026_120749.xml","form_type":"4"}},{"id":722175,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T00:09:53.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":1910,"price":22.95,"value":43834.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":35795,"source":{"system":"sec-edgar","filing":"0001780030-26-000006","document":"form4-07022026_120749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000006/form4-07022026_120749.xml","form_type":"4"}},{"id":722174,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T00:09:53.000Z","date":"2026-06-29","kind":"purchase","planned":false,"acquired":true,"shares":831,"price":23.34,"value":19395.54,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":33885,"source":{"system":"sec-edgar","filing":"0001780030-26-000006","document":"form4-07022026_120749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000006/form4-07022026_120749.xml","form_type":"4"}},{"id":725978,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:40:29.000Z","date":"2026-06-26","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":26.39,"value":2639.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":33054,"source":{"system":"sec-edgar","filing":"0001780030-26-000005","document":"form4-06262026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000005/form4-06262026_110625.xml","form_type":"4"}},{"id":725977,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:40:29.000Z","date":"2026-06-26","kind":"purchase","planned":false,"acquired":true,"shares":1358,"price":25.55,"value":34696.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.335 to $26.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":32954,"source":{"system":"sec-edgar","filing":"0001780030-26-000005","document":"form4-06262026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000005/form4-06262026_110625.xml","form_type":"4"}},{"id":725976,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:40:29.000Z","date":"2026-06-26","kind":"purchase","planned":false,"acquired":true,"shares":4212,"price":24.9,"value":104878.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.27 to $25.2405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":31596,"source":{"system":"sec-edgar","filing":"0001780030-26-000005","document":"form4-06262026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000005/form4-06262026_110625.xml","form_type":"4"}},{"id":725975,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:40:29.000Z","date":"2026-06-26","kind":"purchase","planned":false,"acquired":true,"shares":580,"price":23.61,"value":13693.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.27 to $24.1663, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":27384,"source":{"system":"sec-edgar","filing":"0001780030-26-000005","document":"form4-06262026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000005/form4-06262026_110625.xml","form_type":"4"}},{"id":725974,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:40:29.000Z","date":"2026-06-24","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":27.77,"value":2777.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":26804,"source":{"system":"sec-edgar","filing":"0001780030-26-000005","document":"form4-06262026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000005/form4-06262026_110625.xml","form_type":"4"}},{"id":725973,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:40:29.000Z","date":"2026-06-24","kind":"purchase","planned":false,"acquired":true,"shares":3400,"price":26.98,"value":91732.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.61 to $27.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":26704,"source":{"system":"sec-edgar","filing":"0001780030-26-000005","document":"form4-06262026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000005/form4-06262026_110625.xml","form_type":"4"}},{"id":725972,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:40:29.000Z","date":"2026-06-24","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":25.98,"value":77940.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.58 to $26.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":23304,"source":{"system":"sec-edgar","filing":"0001780030-26-000005","document":"form4-06262026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000005/form4-06262026_110625.xml","form_type":"4"}},{"id":725971,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:40:29.000Z","date":"2026-06-24","kind":"purchase","planned":false,"acquired":true,"shares":2891,"price":25.22,"value":72911.02,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.50 to $25.435, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":20304,"source":{"system":"sec-edgar","filing":"0001780030-26-000005","document":"form4-06262026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000005/form4-06262026_110625.xml","form_type":"4"}},{"id":728226,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T22:58:08.000Z","date":"2026-06-23","kind":"purchase","planned":false,"acquired":true,"shares":425,"price":25.91,"value":11011.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.64 to $26.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":17413,"source":{"system":"sec-edgar","filing":"0001780030-26-000004","document":"form4-06242026_100604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000004/form4-06242026_100604.xml","form_type":"4"}},{"id":728225,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T22:58:08.000Z","date":"2026-06-23","kind":"purchase","planned":false,"acquired":true,"shares":1969,"price":24.84,"value":48909.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.64 to $25.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":16988,"source":{"system":"sec-edgar","filing":"0001780030-26-000004","document":"form4-06242026_100604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000004/form4-06242026_100604.xml","form_type":"4"}},{"id":728224,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T22:58:08.000Z","date":"2026-06-23","kind":"purchase","planned":false,"acquired":true,"shares":6836,"price":24.12,"value":164884.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.62 to $24.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":15019,"source":{"system":"sec-edgar","filing":"0001780030-26-000004","document":"form4-06242026_100604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000004/form4-06242026_100604.xml","form_type":"4"}},{"id":728223,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T22:58:08.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":356,"price":23.95,"value":8526.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.82 to $24.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":8183,"source":{"system":"sec-edgar","filing":"0001780030-26-000004","document":"form4-06242026_100604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000004/form4-06242026_100604.xml","form_type":"4"}},{"id":728222,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T22:58:08.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":3329,"price":23.28,"value":77499.12,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.8003 to $23.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":7827,"source":{"system":"sec-edgar","filing":"0001780030-26-000004","document":"form4-06242026_100604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000004/form4-06242026_100604.xml","form_type":"4"}},{"id":728221,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T22:58:08.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":1583,"price":22.4,"value":35459.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.79 to $22.7733, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":4498,"source":{"system":"sec-edgar","filing":"0001780030-26-000004","document":"form4-06242026_100604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000004/form4-06242026_100604.xml","form_type":"4"}},{"id":728220,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T22:58:08.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":1118,"price":20.82,"value":23276.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.62 to $21.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":2915,"source":{"system":"sec-edgar","filing":"0001780030-26-000004","document":"form4-06242026_100604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000004/form4-06242026_100604.xml","form_type":"4"}},{"id":728219,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":34270,"kind":"person","name":"STEPHENSON BRIAN C","position":1,"cik":"0001780030","reported_name":"STEPHENSON BRIAN C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T22:58:08.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":1797,"price":20.23,"value":36353.31,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.5765 to $20.545, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by the Brian Stephenson Revocable Trust (the \"Trust\"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."}],"balance_after":1797,"source":{"system":"sec-edgar","filing":"0001780030-26-000004","document":"form4-06242026_100604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000178003026000004/form4-06242026_100604.xml","form_type":"4"}},{"id":728201,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"exercise","planned":false,"acquired":false,"shares":8213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments."}],"balance_after":4107,"derivative":{"exercise_price":1.16,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":8213},"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":728200,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"exercise","planned":false,"acquired":false,"shares":45252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Form 4/A filed on June 16, 2026 (the \"Form 4/A\") contained a clerical error with respect to the expiration date of the reported security. This Form 4 corrects that clerical error to report the expiration date of the reported security as December 1, 2035. All other information reported on the Form 4/A remains unchanged."}],"balance_after":91632,"derivative":{"exercise_price":1.16,"expiration_date":"2035-12-01","underlying":"Common Stock","underlying_shares":45252},"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":728199,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"exercise","planned":false,"acquired":true,"shares":8213,"price":1.16,"value":9527.08,"ownership":{"direct":true},"balance_after":817699,"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":728198,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"exercise","planned":false,"acquired":true,"shares":45252,"price":1.16,"value":52492.32,"ownership":{"direct":true},"balance_after":809486,"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":728197,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":2806,"price":19.76,"value":55446.56,"ownership":{"direct":true},"balance_after":764234,"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":737014,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":37277,"kind":"person","name":"Ramasastry Saira","position":1,"cik":"0001547959","reported_name":"Ramasastry Saira","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T20:49:54.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":13,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001547959-26-000015","document":"form4-06162026_080650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000154795926000015/form4-06162026_080650.xml","form_type":"4"}},{"id":737013,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Preferred Stock","published_at":"2026-06-16T20:38:38.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":761.428,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":761428},"source":{"system":"sec-edgar","filing":"0002111813-26-000009","document":"form4-06162026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000009/form4-06162026_080634.xml","form_type":"4"}},{"id":737012,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-16T20:38:38.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":761428,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."}],"balance_after":761428,"source":{"system":"sec-edgar","filing":"0002111813-26-000009","document":"form4-06162026_080634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000009/form4-06162026_080634.xml","form_type":"4"}},{"id":737011,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":37890,"kind":"person","name":"Hahn Stephen M.","position":1,"cik":"0002137706","reported_name":"Hahn Stephen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-06-16T20:21:10.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":44.763,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer's Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44763},"source":{"system":"sec-edgar","filing":"0002137706-26-000003","document":"form4-06162026_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000213770626000003/form4-06162026_080601.xml","form_type":"4"}},{"id":737010,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":37890,"kind":"person","name":"Hahn Stephen M.","position":1,"cik":"0002137706","reported_name":"Hahn Stephen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T20:21:10.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":13,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0002137706-26-000003","document":"form4-06162026_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000213770626000003/form4-06162026_080601.xml","form_type":"4"}},{"id":737009,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":37890,"kind":"person","name":"Hahn Stephen M.","position":1,"cik":"0002137706","reported_name":"Hahn Stephen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:21:10.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":44763,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer's Series B Preferred Stock."}],"balance_after":44763,"source":{"system":"sec-edgar","filing":"0002137706-26-000003","document":"form4-06162026_080601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000213770626000003/form4-06162026_080601.xml","form_type":"4"}},{"id":737007,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-16T20:16:39.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":136884,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 686,733 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 686,733 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027."}],"balance_after":136884,"derivative":{"exercise_price":1.16,"expiration_date":"2025-11-30","underlying":"Common Stock","underlying_shares":136884},"source":{"system":"sec-edgar","filing":"0002111813-26-000008","document":"form4a-06162026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000008/form4a-06162026_080634.xml","form_type":"4/A","original_submission_date":"2026-02-19"}},{"id":737006,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-16T20:16:39.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":12320,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for a stock option to acquire an aggregate 61,809 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for a stock option to acquire an aggregate 61,809 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments."}],"balance_after":12320,"derivative":{"exercise_price":1.16,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":12320},"source":{"system":"sec-edgar","filing":"0002111813-26-000008","document":"form4a-06162026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000008/form4a-06162026_080634.xml","form_type":"4/A","original_submission_date":"2026-02-19"}},{"id":737005,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Preferred Stock","published_at":"2026-06-16T20:16:39.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":761.428,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. (\"HoldCo\") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the \"Merger Agreement\"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (\"Second Merger Sub\"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock (\"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. (\"HoldCo\") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the \"Merger Agreement\"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (\"Second Merger Sub\"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock (\"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."}],"balance_after":761428,"derivative":{"underlying":"Common Stock","underlying_shares":761428},"source":{"system":"sec-edgar","filing":"0002111813-26-000008","document":"form4a-06162026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000008/form4a-06162026_080634.xml","form_type":"4/A","original_submission_date":"2026-02-19"}},{"id":740823,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":39070,"kind":"person","name":"Gerry Christopher","position":1,"cik":"0002097951","reported_name":"Gerry Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & PEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T01:12:57.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The stock option grant was approved by the Issuer's Board of Directors on April 10, 2026, subject to stockholder approval of the 2026 Equity Incentive Plan, which approval was obtained on June 10, 2026. The exercise price reflects the closing price of the Issuer's common stock on April 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":220000,"derivative":{"exercise_price":29.89,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0002097951-26-000001","document":"form4-06132026_010653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000209795126000001/form4-06132026_010653.xml","form_type":"4"}},{"id":740816,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:35:33.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":11.41,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001238120-26-000011","document":"form4-06132026_120629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000123812026000011/form4-06132026_120629.xml","form_type":"4"}},{"id":740815,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":39067,"kind":"person","name":"Holmen Bob","position":1,"cik":"0001843508","reported_name":"Holmen Bob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:33:39.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on June 10, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":11.41,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001843508-26-000002","document":"form4-06132026_120635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000184350826000002/form4-06132026_120635.xml","form_type":"4"}},{"id":757981,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43020,"kind":"organization","name":"Cambrian BioPharma Inc","position":1,"cik":"0001797409","reported_name":"Cambrian BioPharma Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T21:21:50.000Z","date":"2026-06-01","kind":"sale","planned":false,"acquired":false,"shares":476,"price":21.14,"value":10062.64,"ownership":{"direct":true},"balance_after":130142,"source":{"system":"sec-edgar","filing":"0000897069-26-001299","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706926001299/form4.xml","form_type":"4"}},{"id":757980,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43020,"kind":"organization","name":"Cambrian BioPharma Inc","position":1,"cik":"0001797409","reported_name":"Cambrian BioPharma Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T21:21:50.000Z","date":"2026-06-01","kind":"sale","planned":false,"acquired":false,"shares":24524,"price":20,"value":490480.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":130618,"source":{"system":"sec-edgar","filing":"0000897069-26-001299","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706926001299/form4.xml","form_type":"4"}},{"id":757979,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2026-06-01T21:20:06.000Z","date":"2026-06-01","kind":"sale","planned":false,"acquired":false,"shares":476,"price":21.14,"value":10062.64,"ownership":{"direct":true},"balance_after":130142,"source":{"system":"sec-edgar","filing":"0000897069-26-001297","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706926001297/form4.xml","form_type":"4"}},{"id":757978,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":43019,"kind":"person","name":"Peyer James","position":1,"cik":"0001843594","reported_name":"Peyer James","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks below"}}],"security":"Common Stock","published_at":"2026-06-01T21:20:06.000Z","date":"2026-06-01","kind":"sale","planned":false,"acquired":false,"shares":24524,"price":20,"value":490480.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":130618,"source":{"system":"sec-edgar","filing":"0000897069-26-001297","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000089706926001297/form4.xml","form_type":"4"}},{"id":778203,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":1108,"price":33.38,"value":36985.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Represents sales of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":133986,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778202,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":300,"price":32.2467,"value":9674.01,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Represents VWAP of sales of 300 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $32.0625 to $32.615."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":133986,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778201,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":4423,"price":31.3843,"value":138812.7589,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Represents VWAP of sales of 4,423 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $30.9852 to $31.813."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":133986,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778200,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":205,"price":29.7146,"value":6091.493,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents VWAP of sales of 205 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $29.695 to $30.50."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":133986,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778199,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":2115,"price":28.9417,"value":61211.6955,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents VWAP of sales of 2,115 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $28.5071 to $29.3167."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":133986,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778198,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-07","kind":"purchase","planned":false,"acquired":true,"shares":1108,"price":33.38,"value":36985.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents VWAP of purchases of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":133986,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778197,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-06","kind":"sale","planned":false,"acquired":false,"shares":45,"price":31.9628,"value":1438.326,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents VWAP of sales of 45 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $31.80 to $32.17."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":141029,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778196,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-06","kind":"sale","planned":false,"acquired":false,"shares":1214,"price":31.0227,"value":37661.5578,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents VWAP of sales of 1,214 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $30.64 to $31.345."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":141029,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778195,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-06","kind":"purchase","planned":false,"acquired":true,"shares":1104,"price":31.02,"value":34246.08,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents purchases of 1,104 shares of the Company's Common Stock on April 6, 2026 at $31.02 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":141029,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778194,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":1134,"price":34.8007,"value":39463.9938,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents VWAP of sales of 1,134 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $34.40 to $35.25."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":144974,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778193,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":374,"price":33.347,"value":12471.778,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents VWAP of sales of 374 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.23 to $33.45."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":144974,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778192,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":1794,"price":32.6041,"value":58491.7554,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents VWAP of sales of 1,794 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $32.22 to $33.1251."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":144974,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778191,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":1265,"price":31.751,"value":40165.015,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents VWAP of sales of 1,265 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $31.21 to $32.15."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":144974,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778190,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":3099,"price":30.8638,"value":95646.9162,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents VWAP of sales of 3,099 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $30.1332 to $31.1212."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":144974,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778189,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-02","kind":"purchase","planned":false,"acquired":true,"shares":701,"price":35.5472,"value":24918.5872,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents VWAP of purchases of 701 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $35.4481 to $35.91."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":144974,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778188,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-02","kind":"purchase","planned":false,"acquired":true,"shares":1276,"price":34.7524,"value":44344.0624,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents VWAP of purchases of 1,276 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.97 to $34.90."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":144974,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778187,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:24:06.000Z","date":"2026-04-02","kind":"purchase","planned":false,"acquired":true,"shares":26,"price":33.4704,"value":870.2304,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents volume-weighted average price (\"VWAP\") of purchases of 26 shares of common stock (\"Common Stock\"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the \"Company\") on April 2, 2026 at prices ranging from $32.90 to $33.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":144974,"source":{"system":"sec-edgar","filing":"0001104659-26-062608","document":"tm2614687-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062608/tm2614687-4_4seq1.xml","form_type":"4"}},{"id":778220,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-04-01","kind":"sale","planned":false,"acquired":false,"shares":46,"price":34.7464,"value":1598.3344,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Represents VWAP of sales of 46 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $34.5271 to $35.3850."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":147731,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778219,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-04-01","kind":"sale","planned":false,"acquired":false,"shares":1104,"price":31.52,"value":34798.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Represents sales of 1,104 shares of the Company's Common Stock on April 1, 2026 at $31.52 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":147731,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778218,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-04-01","kind":"purchase","planned":false,"acquired":true,"shares":3401,"price":35.4554,"value":120583.8154,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Represents VWAP of purchases of 3,401 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $35.06 to $35.90."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":147731,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778217,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-04-01","kind":"purchase","planned":false,"acquired":true,"shares":1613,"price":34.5863,"value":55787.7019,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents VWAP of purchases of 1,613 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $34.04 to $34.98."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":147731,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778216,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-04-01","kind":"purchase","planned":false,"acquired":true,"shares":1161,"price":31.5309,"value":36607.3749,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents VWAP of purchases of 1,161 shares of the Company's Common Stock on April 1, 2026 at prices ranging from $31.52 to $32.50."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":147731,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778215,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":87,"price":31.52,"value":2742.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents sales of 87 shares of the Company's Common Stock on March 31, 2026 at $31.52 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778214,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":5,"price":28.405,"value":142.025,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents sales of 5 shares of the Company's Common Stock on March 31, 2026 at $28.4050 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778213,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":57,"price":27.1147,"value":1545.5379,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents sales of 57 shares of the Company's Common Stock on March 31, 2026 at $27.1147 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778212,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":1251,"price":25.1676,"value":31484.6676,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents VWAP of sales of 1,251 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $25.13 to $25.45."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778211,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":191,"price":24.2843,"value":4638.3013,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents VWAP of sales of 191 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $23.91 to $24.6089."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778210,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":411,"price":32.5962,"value":13397.0382,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents VWAP of purchases of 411 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $32.4343 to $32.91."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778209,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1957,"price":31.4512,"value":61549.9984,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents VWAP of purchases of 1,957 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $31.215 to $31.17."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778208,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":186,"price":30.4754,"value":5668.4244,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents VWAP of purchases of 186 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $30.1693 to $30.73."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778207,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":17,"price":27.7838,"value":472.3246,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents VWAP of purchases of 17 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $27.525 to $28.405."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778206,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1048,"price":26.7259,"value":28008.7432,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents VWAP of purchases of 1,048 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $26.2587 to $27.1994."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778205,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1770,"price":25.3209,"value":44817.993,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents VWAP of purchases of 1,770 shares of the Company's Common Stock on March 31, 2026 at prices ranging from $25.13 to $26.12."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778204,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:57.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":616,"price":24.6857,"value":15206.3912,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents volume-weighted average price (\"VWAP\") of purchases of 616 shares of common stock (\"Common Stock\"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the \"Company\") on March 31, 2026 at prices ranging from $23.91 to $24.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":146657,"source":{"system":"sec-edgar","filing":"0001104659-26-062605","document":"tm2614687-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062605/tm2614687-3_4seq1.xml","form_type":"4"}},{"id":778186,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-30","kind":"sale","planned":false,"acquired":false,"shares":370,"price":27.68,"value":10241.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Represents sales of 370 shares of the Company's Common Stock on March 30, 2026 at $27.68 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":145678,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778185,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-30","kind":"sale","planned":false,"acquired":false,"shares":518,"price":25.8501,"value":13390.3518,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Represents VWAP of sales of 518 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $25.13 to $26.0734."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":145678,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778184,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-30","kind":"purchase","planned":false,"acquired":true,"shares":370,"price":27.68,"value":10241.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Represents purchases of 370 shares of the Company's Common Stock on March 30, 2026 at $27.68 per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":145678,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778183,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-30","kind":"purchase","planned":false,"acquired":true,"shares":1176,"price":26.7,"value":31399.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents VWAP of purchases of 1,176 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $26.50 to $26.90."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":145678,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778182,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-30","kind":"purchase","planned":false,"acquired":true,"shares":4995,"price":25.99,"value":129820.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents VWAP of purchases of 4,995 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $25.50 to $26.48."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":145678,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778181,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-30","kind":"purchase","planned":false,"acquired":true,"shares":2992,"price":25.0784,"value":75034.5728,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents VWAP of purchases of 2,992 shares of the Company's Common Stock on March 30, 2026 at prices ranging from $24.495 to $25.1856."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":145678,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778180,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":36,"price":27.369,"value":985.284,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents VWAP of sales of 36 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $27.2322 to $27.68."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":142360,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778179,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-27","kind":"sale","planned":false,"acquired":false,"shares":469,"price":26.7652,"value":12552.8788,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents VWAP of sales of 469 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $26.21 to $26.95."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":142360,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778178,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-27","kind":"purchase","planned":false,"acquired":true,"shares":294,"price":28.1301,"value":8270.2494,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents VWAP of purchases of 294 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $28.10 to $28.60."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":142360,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778177,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-27","kind":"purchase","planned":false,"acquired":true,"shares":4384,"price":27.2826,"value":119606.9184,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents VWAP of purchases of 4,384 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $26.9750 to $27.68."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":142360,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778176,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-27","kind":"purchase","planned":false,"acquired":true,"shares":10643,"price":26.2933,"value":279839.5919,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents VWAP of purchases of 10,643 shares of the Company's Common Stock on March 27, 2026 at prices ranging from $25.9197 to $26.88."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":142360,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778175,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-26","kind":"sale","planned":false,"acquired":false,"shares":1274,"price":28.6882,"value":36548.7668,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents VWAP of sales of 1,274 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $28.07 to $28.7651."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":131370,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778174,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-26","kind":"sale","planned":false,"acquired":false,"shares":583,"price":26.8797,"value":15670.8651,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents VWAP of sales of 583 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $26.68 to $27.4650."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":131370,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778173,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-26","kind":"purchase","planned":false,"acquired":true,"shares":1025,"price":29.9788,"value":30728.27,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents VWAP of purchases of 1,025 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $29.79 to $30.105."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":131370,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778172,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-26","kind":"purchase","planned":false,"acquired":true,"shares":2601,"price":28.8539,"value":75048.9939,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents VWAP of purchases of 2,601 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $28.7072 to $29.51."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":131370,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778171,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-26","kind":"purchase","planned":false,"acquired":true,"shares":1327,"price":27.9467,"value":37085.2709,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents VWAP of purchases of 1,327 shares of the Company's Common Stock on March 26, 2026 at prices ranging from $27.70 to $28.4163."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":131370,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":778170,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":47115,"kind":"organization","name":"MILLENNIUM MANAGEMENT LLC","position":1,"cik":"0001273087","reported_name":"MILLENNIUM MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47116,"kind":"organization","name":"ICS OPPORTUNITIES II LLC","position":2,"cik":"0001783647","reported_name":"ICS OPPORTUNITIES II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47117,"kind":"organization","name":"MILLENNIUM GROUP MANAGEMENT LLC","position":3,"cik":"0001446830","reported_name":"MILLENNIUM GROUP MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47118,"kind":"person","name":"ENGLANDER ISRAEL A","position":4,"cik":"0001017456","reported_name":"ENGLANDER ISRAEL A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T20:22:04.000Z","date":"2026-03-26","kind":"purchase","planned":false,"acquired":true,"shares":778,"price":27.2267,"value":21182.3726,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents volume-weighted average price (\"VWAP\") of purchases of 778 shares of common stock (\"Common Stock\"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the \"Company\") on March 26, 2026 at prices ranging from $26.66 to $27.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any."}],"balance_after":131370,"source":{"system":"sec-edgar","filing":"0001104659-26-062603","document":"tm2614687-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000110465926062603/tm2614687-2_4seq1.xml","form_type":"4"}},{"id":809254,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29077,"kind":"person","name":"Craver Josiah","position":1,"cik":"0002038400","reported_name":"Craver Josiah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFO & PAO"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-14T21:18:25.000Z","date":"2026-04-10","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the date of grant, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":29.89,"expiration_date":"2036-04-09","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0002038400-26-000001","document":"form4-04142026_090421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000203840026000001/form4-04142026_090421.xml","form_type":"4"}},{"id":809252,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":39068,"kind":"person","name":"Donenberg Phillip B.","position":1,"cik":"0001238120","reported_name":"Donenberg Phillip B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-14T21:15:54.000Z","date":"2026-04-10","kind":"grant","planned":false,"acquired":true,"shares":23100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a supplemental option grant to align the Reporting Person's total initial director option grant with the Company's non-employee director compensation policy, which was amended on April 10, 2026 to provide for an initial option grant of 25,000 shares to new directors. The Reporting Person previously received an initial grant of 1,900 shares in February 2026; this supplemental grant of 23,100 shares reflects the difference."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or April 10, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":23100,"derivative":{"exercise_price":29.89,"expiration_date":"2036-04-09","underlying":"Common Stock","underlying_shares":23100},"source":{"system":"sec-edgar","filing":"0001238120-26-000006","document":"form4-04142026_090450.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000123812026000006/form4-04142026_090450.xml","form_type":"4"}},{"id":894786,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-20T02:45:04.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":1239305,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares shall vest on February 19, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1239305,"derivative":{"exercise_price":27.22,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":1239305},"source":{"system":"sec-edgar","filing":"0002111813-26-000004","document":"form4-02202026_020201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000004/form4-02202026_020201.xml","form_type":"4"}}],"next_cursor":"2026-02-20T02:45:04.000000Z,894786"}